Developing a prediction model in a large case-control study for the early detection of bladder cancer

Bladder cancer (BCa) is a lethal cancer, but early-detection offers an opportunity to improve prognosis. Our objective was to develop a urine-based multi-marker panel for BCa detection across multiple longitudinal cohort studies in a nested case-control study. Longitudinal cohorts included healthy participants enrolled in the Southern Community Cohort Study (SCCS), Singapore Chinese Health Study (SCHS), Shanghai Women/Men Health Study (SWMHS), and Multiethnic Cohort (MEC). We measured the levels of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGF) in spot-voided urine samples using the multiplex immunoassay Oncuria. Single urine specimens collected from 274 participants who would go on to develop BCa in the ensuing 3‒60 months (i.e., cases) were age/sex-matched to 274 cancer-free controls. We used generalized estimating equation models, logistic regression analysis, and random forest algorithms to analyze the data. Differences in the individual biomarker levels between cases and controls were noted for ANG at 12 months (p = 0.046), APOE at 12 months (p < 0.001), MMP10 at 12 months (p = 0.009), PAI1 at 12 months (p = 0.005), SDC1 at 12 months (p = 0.003), 48 months (p = 0.029) and 60 months (p = 0.002), and VEGF at 12 months (p < 0.001). Lastly, the best preliminary model to predict subsequent BCa was IL8, CA9, PAI1, APOE and clinical features which had an AUC of 0.98, accuracy of 0.94 with a sensitivity of 0.88 and specificity of 1.00. Additional testing is needed; however preliminary results demonstrate that a multiplex immunoassay may be able to facilitate the early detection of BCa in at-risk patients. Identification of BCa at an early stage may lead to improved patient outcomes. Using large multinational patient populations, we tested the performance of the Oncuria multiplex assay to accurately predict the risk of developing bladder cancer by simultaneously analyzing the concentrations of 10 protein biomarkers in urine samples.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2025-12-05
DOI
https://doi.org/10.1186/s12967-025-07511-1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Developing a prediction model in a large case-control study for the early detection of bladder cancer

Lynne Ross Wilkens, Charles J. Rosser, Jane C. Figueiredo, Ian Pagano et al.
Journal of Translational Medicine
Bladder and Urothelial Cancer Treatments
article

Developing a prediction model in a large case-control study for the early detection of bladder cancer

Lynne Ross Wilkens, Charles J. Rosser, Jane C. Figueiredo, Ian Pagano, Gong Yang, Michael Luu, Hideki Furuya, Loı̈c Le Marchand, Martha J. Shrubsole, Jian‐Min Yuan, Sunao Tanaka, Woon‐Puay Koh
article en

Abstract

Bladder cancer (BCa) is a lethal cancer, but early-detection offers an opportunity to improve prognosis. Our objective was to develop a urine-based multi-marker panel for BCa detection across multiple longitudinal cohort studies in a nested case-control study. Longitudinal cohorts included healthy participants enrolled in the Southern Community Cohort Study (SCCS), Singapore Chinese Health Study (SCHS), Shanghai Women/Men Health Study (SWMHS), and Multiethnic Cohort (MEC). We measured the levels of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGF) in spot-voided urine samples using the multiplex immunoassay Oncuria. Single urine specimens collected from 274 participants who would go on to develop BCa in the ensuing 3‒60 months (i.e., cases) were age/sex-matched to 274 cancer-free controls. We used generalized estimating equation models, logistic regression analysis, and random forest algorithms to analyze the data. Differences in the individual biomarker levels between cases and controls were noted for ANG at 12 months (p = 0.046), APOE at 12 months (p < 0.001), MMP10 at 12 months (p = 0.009), PAI1 at 12 months (p = 0.005), SDC1 at 12 months (p = 0.003), 48 months (p = 0.029) and 60 months (p = 0.002), and VEGF at 12 months (p < 0.001). Lastly, the best preliminary model to predict subsequent BCa was IL8, CA9, PAI1, APOE and clinical features which had an AUC of 0.98, accuracy of 0.94 with a sensitivity of 0.88 and specificity of 1.00. Additional testing is needed; however preliminary results demonstrate that a multiplex immunoassay may be able to facilitate the early detection of BCa in at-risk patients. Identification of BCa at an early stage may lead to improved patient outcomes. Using large multinational patient populations, we tested the performance of the Oncuria multiplex assay to accurately predict the risk of developing bladder cancer by simultaneously analyzing the concentrations of 10 protein biomarkers in urine samples.

Journal of Translational MedicineVol. 24(1)
Agency for Science, Technology and Research (SG), University of Hawaiʻi at Mānoa (US), Cedars-Sinai Medical Center (US), University of Hawaii System (US), National University of Singapore (SG), University of Pittsburgh (US), Vanderbilt University (US), Singapore Institute for Clinical Sciences (SG), UPMC Hillman Cancer Center (US), Nonagen Bioscience (United States) (US), University of Hawaii Cancer Center
Openalex Percentile: Top 42%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.